Maker of Tumor Treating Fields devices, a wearable cancer therapy using electric fields to disrupt tumor cell division.
Maker of Tumor Treating Fields devices, a wearable cancer therapy using electric fields to disrupt tumor cell division.
Bills insurers for each month a patient stays on therapy, with the device and support services included, so revenue follows the number of active patients and how long they stay on treatment rather than one-off device sales. Glioblastoma, an aggressive brain cancer, is the long-standing franchise; the 2024 US approval of the lung-cancer version opened a second.
Moat: narrow (IP / patents, regulatory licence). Patented TTFields technology is a unique treatment modality with no direct device competitor.
Headquarters: Root, Switzerland · Founded: 2000 · Employees: 1,605
Size NovoCure (NVCR) is a United States Health Care company (Medical Specialties) with a market value of $1.25B, the 2090th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.73 on 18 Nov 2026.
Performance Over six months the shares fell 39.5%, against -14.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 12.9% over the last twelve months (peer median +10.8%); the operating margin is -17.2% (peer median 11.6%).
Valuation It trades at 1.4× enterprise value to sales against a peer median of 3.8× (2nd cheapest of 20).
Capital Return on invested capital runs 100.4 points below its cost of capital (9.8% WACC).
Short interest Short interest is 11.1% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $725M | $655M | $605M | $509M | $538M |
| Revenue growth | — | +8% | +19% | -5% | — |
| Gross profit | $559M | $490M | $469M | $382M | $424M |
| EBITDA | -$107M | -$137M | -$156M | -$215M | -$78.3M |
| Net income | -$122M | -$136M | -$169M | -$207M | -$92.5M |
| Free cash flow | -$24.6M | -$75.7M | -$69.2M | -$100M | $9.43M |
| Capital expenditure | $23.9M | $26.6M | $42.9M | $27.1M | $21.4M |
| Total debt | $232M | $248M | $683M | $604M | $590M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| NovoCure NVCR | $1.25B | -40% | +13% | -17% | 1.4× | n/a |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NVCR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -31.7% | -1.9% | 2nd lowest of 21 |
| 6-month return | -39.5% | -14.3% | 3rd lowest of 20 |
| Distance from 52-week high | -50.0% | -38.5% | 6th lowest of 21 |
| Revenue growth (TTM) | +12.9% | +10.8% | 9th highest of 19 |
| Operating margin | -17.2% | 11.6% | 2nd lowest of 20 |
| EV / Sales | 1.4× | 3.8× | 2nd cheapest of 20 |
| ROIC minus cost of capital | -100.4 pp | +0.2 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | 1.4× | n/a | n/a |
| Sansure Biotech 688289.SS | China | $1.24B | -17% | -1% | 1% | 3.8× | n/a | n/a |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 3.4× | 35.1% | +7.9% |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 16% | 5.0× | 10.3% | +40.3% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 10.6× | n/a | n/a |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 3.3× | n/a | n/a |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 15.4× | 22.8% | +23.6% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 13.4× | 20.7% | +27.6% |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | 1.4× | n/a | n/a |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 3.8× | 8.3% | +16.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 4.7× | 11.3% | -3.5% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 5.8× | 1.7% | +9.9% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 1.6× | 31.6% | +9.8% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 1.9× | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | 3.7× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | 4.7× | n/a | n/a |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 2.0× | 9.5% | +18.3% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 6.0× | 2.9% | +14.6% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 4.0× | -9.2% | +34.5% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 1.7× | 5.9% | +3.6% |